Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 4/20 | 0.68 |
| ▸ | IL1B | P01584 | 2/20 | 0.68 |
| ▸ | RAB9A | P51151 | 4/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27459971 | 1.00 | CASP1 (0.68) | CASP1IL1BRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL27546462 | 0.90 | CASP1 (0.64) | CASP1IL1BRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL952004 | 0.90 | CASP1 (0.64) | CASP1IL1BRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL12450653 | 0.85 | CASP1 (0.70) | CASP1IL1BRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL27551609 | 0.81 | CASP1 (1.00) | CASP1IL1B | |
| SCHEMBL12914538 | 0.81 | CASP1 (1.00) | CASP1IL1B | |
| SCHEMBL12450460 | 0.81 | CASP1 (0.88) | CASP1IL1BRAB9APOLB | |
| SCHEMBL8648026 | 0.81 | ALDH1A1 (0.58) | CASP1IL1BRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL952097 | 0.80 | NPC1 (0.55) | CASP1IL1BRAB9ANPC1POLB | |
| SCHEMBL951246 | 0.80 | CASP1 (0.54) | CASP1IL1BRAB9ANPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110015371-A1 | Inhibitors of interleukin-1 beta converting enzyme | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-01-20 | — | — | US | disclosed |
| CN-1192035-C | Inhibitors of interleukin-1'beta' converting enzyme | VERTEX PHARMA (US) | 2005-03-09 | — | — | CN | disclosed |
| CN-1159196-A | Inhibitors of interleukin-1'beta' converting enzyme | VERTEX PHARMA (US) | 1997-09-10 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015371-A1 | Inhibitors of interleukin-1 beta converting enzyme | IL1B, IL1A, IL1R1 | CASP1 5/4885IL1B 1/4885RAB9A 2305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.